Mar 28, 2020, 18:53 pm
The US Food and Drug Administration, recently, awarded Abbott Laboratories the emergency use authorization for the ID Now COVID-19 test. The molecular test for the novel coronavirus strain is one of the growing numbers of point of care diagnostic tests that got approval from the agency. The ID NOW COVID-19 test, according to Abbott, is capable of delivering positive results in as fast as 5 minutes and negative results in just 13 minutes.
The ID NOW COVID-19 test could be used in various temporary screening locations, nursing homes, doctor's office labs, and clinics to detect the novel coronavirus strain in less than half an hour. The device is compact and portable, making it an ideal screening for almost any kind of health care setup. Abbott Laboratories plans to produce 50,000 tests per day beginning Apr. 1, John Frels, the company's Vice President of Research and Development, reveals.
Abbott President and Chief Operating Officer Robert Ford says that "with rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots." The U.S. is struggling to provide an ample amount of COVID-19 test kits to detect the novel coronavirus with the outbreak now threatening to overwhelm hospitals in Washington, New York, and other areas. Initially, the testing was restricted to high-risk people.
But, the USFDA, recently, rushed out diagnostics developed by leading commercial testing companies following issues with the test developed by the Centers for Disease Control and Prevention.
With the ID NOW COVID-19 test, the patient is taken a swab from the back of the throat or nose. It is then mixed with a chemical solution that breaks the virus and deploys its RNA. After that, the mixture is placed into the ID NOW system.
The Abbott ID NOW COVID-19 device is a compact box that weighs below seven pounds. It houses a technology that identifies and magnifies select sequences of the COVID-19 genome and disregards contamination from other viruses.
https://www.ibtimes.com/fda-finally-nods...st-2948407
The ID NOW COVID-19 test could be used in various temporary screening locations, nursing homes, doctor's office labs, and clinics to detect the novel coronavirus strain in less than half an hour. The device is compact and portable, making it an ideal screening for almost any kind of health care setup. Abbott Laboratories plans to produce 50,000 tests per day beginning Apr. 1, John Frels, the company's Vice President of Research and Development, reveals.
Abbott President and Chief Operating Officer Robert Ford says that "with rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots." The U.S. is struggling to provide an ample amount of COVID-19 test kits to detect the novel coronavirus with the outbreak now threatening to overwhelm hospitals in Washington, New York, and other areas. Initially, the testing was restricted to high-risk people.
But, the USFDA, recently, rushed out diagnostics developed by leading commercial testing companies following issues with the test developed by the Centers for Disease Control and Prevention.
With the ID NOW COVID-19 test, the patient is taken a swab from the back of the throat or nose. It is then mixed with a chemical solution that breaks the virus and deploys its RNA. After that, the mixture is placed into the ID NOW system.
The Abbott ID NOW COVID-19 device is a compact box that weighs below seven pounds. It houses a technology that identifies and magnifies select sequences of the COVID-19 genome and disregards contamination from other viruses.
https://www.ibtimes.com/fda-finally-nods...st-2948407